Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.

Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, Sorror ML, Woolston DW, Monahan T, Scott BL, Deeg HJ.

Haematologica. 2019 Jul 9. pii: haematol.2019.218677. doi: 10.3324/haematol.2019.218677. [Epub ahead of print]

2.

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):390-395. doi: 10.1016/j.clml.2019.03.003. Epub 2019 Mar 11.

PMID:
30948330
3.

Outpatient induction and consolidation care strategies in acute myeloid leukemia.

Halpern AB, Walter RB, Estey EH.

Curr Opin Hematol. 2019 Mar;26(2):65-70. doi: 10.1097/MOH.0000000000000481.

PMID:
30585894
4.

CLAG-M with dose-escalated mitoxantrone for adults with acute myeloid leukemia.

Halpern AB, Walter RB.

Oncotarget. 2018 Nov 27;9(93):36543-36544. doi: 10.18632/oncotarget.26383. eCollection 2018 Nov 27. No abstract available.

5.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. No abstract available.

6.

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH.

Leuk Lymphoma. 2019 Apr;60(4):1023-1029. doi: 10.1080/10428194.2018.1516036. Epub 2018 Oct 2.

PMID:
30277112
7.

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML).

Acharya UH, Halpern AB, Wu QV, Voutsinas JM, Walter RB, Yun S, Kanaan M, Estey EH.

J Drug Assess. 2018 Jul 10;7(1):51-53. doi: 10.1080/21556660.2018.1492925. eCollection 2018.

8.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.

9.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

10.

Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit.

Halpern AB, Culakova E, Walter RB, Lyman GH.

JAMA Oncol. 2017 Mar 1;3(3):374-381. doi: 10.1001/jamaoncol.2016.4858.

11.

Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

Leukemia. 2016 Jul;30(7):1456-64. doi: 10.1038/leu.2016.46. Epub 2016 Feb 29.

12.

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.

13.

Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB.

Blood. 2015 Dec 24;126(26):2790-7. doi: 10.1182/blood-2015-07-627323. Epub 2015 Oct 26. Review. No abstract available.

14.

Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE.

Oral Oncol. 2009 Oct;45(10):e155-60. doi: 10.1016/j.oraloncology.2009.05.637. Epub 2009 Jul 7.

Supplemental Content

Loading ...
Support Center